Olema Oncology to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) will participate in three investor conferences in November 2025: a Guggenheim fireside chat on Nov 10, 2025 at 10:30 a.m. ET in Boston; a UBS presentation on Nov 12, 2025 at 8:00 a.m. ET in Palm Beach; and a Jefferies London fireside chat on Nov 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET in London.
Live webcasts and recordings will be available, as permitted by event hosts, in the Events and Presentations section of Olema’s investor relations site at ir.olema.com.
Details
News Market Reaction – OLMA
On Nov 4, the first trading day after this news, OLMA closed 2.61% below the previous close.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Guggenheim 2nd Annual Healthcare Innovation Conference
Date and Time: November 10, 2025 at 10:30 a.m. ET
Format: Fireside Chat
Location: Boston, MA
UBS Global Healthcare Conference 2025
Date and Time: November 12, 2025 at 8:00 a.m. ET
Format: Presentation
Location: Palm Beach, FL
2025 Jefferies London Healthcare Conference
Date and Time: November 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET
Format: Fireside Chat
Location: London
Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.